R. Vidal et al., INCIDENCE AND SIGNIFICANCE OF ACID-FAST BACILLI IN SPUTUM SMEARS AT THE END OF ANTITUBERCULOUS TREATMENT, Chest, 109(6), 1996, pp. 1562-1565
Objective: A group of patients with pulmonary tuberculosis (PT) who re
ceived and correctly completed antituberculous therapy were studied to
determine the incidence and significance of positive acid-fast bacill
i (AFB) in sputum smears at the end of this treatment. Design: Retrosp
ective chart review of persons with bacteriologically proved PT. Patie
nts: Of 1,052 patients diagnosed as having PT between 1988 and 1992, 3
53 who fulfilled the following criteria were included in the study: (1
) diagnosis established by positive AFB and positive culture in sputum
smears; (2) no previous antituberculous treatment had been received;
(3) HIV serologic test results were negative; (4) treatment was correc
tly completed; (5) they were followed up throughout the period of trea
tment; and (6) expectoration was still present at the end of treatment
and at least two spontaneous sputum samples could be obtained. Result
s: Positive AFB of sputum smears were found at the end of treatment in
10 (2.2%) of the 453 patients studied, Five patients had only one pos
itive smear, and the other five had more than one. Of these ten cases,
sputum culture was negative in eight, which were considered to be unv
iable bacilli, and positive for nontuberculous mycobacteria in two. Cl
inical symptoms or worsening on chest radiograph were observed only in
one patient with unviable bacilli, but they were caused by a concomit
ant nonspecific respiratory tract infection. Conclusions: Positive AFB
smear results at the end of completed treatment regimens analyzed in
this study have occurred because of unviable bacilli and nontuberculou
s mycobacteria colonization. The presence of more than one positive sm
ear seems not to increase the probability of treatment failure and is
more frequently due to nontuberculous mycobacteria, Results of culture
can thus be awaited without the need to prolong or modify antitubercu
lous therapy.